Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Multiple Cancer Types

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Germ Cell (Pediatrics), Gynecologic, Ovarian
III
Borinstein, Scott
NCT03067181
COGAGCT1531


Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-Cel) Out-of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia

Leukemia

Leukemia
N/A
Oluwole, Olalekan
VICC-CTT25006

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head/Neck

Head/Neck
Early I
Kobayashi, Kenji
VICCHN26044

A Window of Opportunity Study of Low-Dose Neoadjuvant Nivolumab in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head/Neck

Head/Neck
I
Rosenthal, Eben
VICCHN25078

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Neuro-Oncology

Neuro-Oncology
Early I
Morone, Peter
VICCHN25072

Safety and Functional Outcomes Following Laryngeal Transplantation

Head/Neck

Head/Neck
N/A
Gelbard, Alexander
VICCHN2293

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in patients with symptomatic severe aortic stenosis)

Not Available
N/A
Goel, Kashish
VALV0019

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Kidney (Renal Cell)

This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
Kidney (Renal Cell)
II
Rini, Brian
NCT07188896
VICCURO24517

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Breast

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Breast
II
Abramson, Vandana
NCT07102381
VICCBRE25004

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.